|
LLPH expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.59489976780947E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.99420002733319E-09 |
| Normal-vs-Stage2 |
5.180500E-03 |
| Normal-vs-Stage3 |
2.25950003152064E-09 |
| Normal-vs-Stage4 |
8.06489997007276E-09 |
| Stage1-vs-Stage2 |
1.452420E-01 |
| Stage1-vs-Stage3 |
3.224800E-01 |
| Stage1-vs-Stage4 |
5.733700E-02 |
| Stage2-vs-Stage3 |
3.468400E-02 |
| Stage2-vs-Stage4 |
1.066250E-02 |
| Stage3-vs-Stage4 |
2.434600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.20980045162867E-10 |
| Normal-vs-AfricanAmerican |
1.614810E-04 |
| Normal-vs-Asian |
2.26829999999678E-05 |
| Caucasian-vs-AfricanAmerican |
9.040000E-01 |
| Caucasian-vs-Asian |
7.170000E-01 |
| AfricanAmerican-vs-Asian |
7.458800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.09050024355417E-10 |
| Normal-vs-Female |
1.29160004913587E-09 |
| Male-vs-Female |
1.684850E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.91639995381377E-09 |
| Normal-vs-Age(41-60Yrs) |
2.04350003585319E-09 |
| Normal-vs-Age(61-80Yrs) |
8.21610000034667E-08 |
| Normal-vs-Age(81-100Yrs) |
1.604030E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.030800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.184400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.690000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.995600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.035800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.020400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.874000E-02 |
| Classical-VS-Follicular |
4.894400E-01 |
| Classical-VS-Other |
5.571600E-01 |
| Classical-VS-Normal |
1.32230000282618E-08 |
| Tall-VS-Follicular |
3.857600E-02 |
| Tall-VS-Other |
9.267200E-01 |
| Tall-VS-Normal |
1.77369996468002E-09 |
| Follicular-VS-Other |
4.072600E-01 |
| Follicular-VS-Normal |
1.835550E-04 |
| Other-VS-Normal |
6.591700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.1284999984772E-08 |
| Normal-vs-N1 |
5.34572386357013E-12 |
| N0-vs-N1 |
8.791500E-04 |
|
|
